Alnylam Pharmaceuticals
ALNY
#563
Rank
A$59.63 B
Marketcap
A$449.66
Share price
-0.37%
Change (1 day)
21.15%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): A$0.15

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is A$0.13. In 2023 the company made an earnings per share (EPS) of A-$4.92 an increase over its 2022 EPS that were of A-$12.96.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)A$0.15
2023A-$4.92-62%
2022A-$12.9629.03%
2021A-$10.04-3.36%
2020A-$10.39-8.48%
2019A-$11.357.67%
2018A-$10.5439.74%
2017A-$7.5512.94%
2016A-$6.6838.84%
2015A-$4.81-32.88%
2014A-$7.17259.44%
2013A-$1.99-31.25%
2012A-$2.90

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
A$10.27 8,077.78%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
A$2.88 2,194.62%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
A$60.14 47,811.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
A-$3.82-3,144.44%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
A-$1.02-911.11%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
A-$0.33-366.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
A$1.73 1,277.78%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
A-$1.74-1,488.89%๐Ÿ‡บ๐Ÿ‡ธ USA